Clinical trials: Cardiotoxicity, active
Cardiotoxicity, HER2-positive Breast Cancer
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system.
- Trial name
- HER2BIC (NCT05406635)
- Testing
- Biomarkers: Troponins and natriuretic peptides
- Where
- 3 sites in Denmark
- Volunteers
- 191 people
- Sponsor
- Odense University Hospital
Heart Failure
Heart Failure in Women: Epidemiological and Prognostic Insights
Heart failure (HF) is a leading cause of hospital admission in older adults and women account for more than half of these admissions, yet they remain under-represented in prospective HF cohorts.
- Trial name
- HER-HF (NCT07847983)
- Where
- 24 sites in Spain
- Volunteers
- 430 people
- Sponsor
- Carolina Ortiz Cortes
Cardiotoxicity
Cardioprotection Effect of Linagliptin
1. Background and Rationale Breast cancer is one of the most common malignancies affecting women worldwide and represents a major health burden in Egypt.
- Trial name
- Linagliptin (NCT07852546)
- Testing
- Doxorubicin, Empaglifloz 5 mg orally once daily
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Tanta University
Cardiotoxicity, Cardiac Biomarkers
Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)
Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. Blood tests such as cardiac troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can help clinicians investigate possible heart injury, but…
- Conditions
- Cardiotoxicity, Cardiac Biomarkers, Cancer
- Trial name
- PRIME-ICI (NCT07864727)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Cancer and / or Hematological Malignancy, Anthracycline-induced Cardiotoxicity
BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry
The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across…
- Trial name
- BHF-COLLATE (NCT07864467)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Cardiotoxicity, Cancer
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment.
- Conditions
- Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction
- Trial name
- NCT07776964
- Testing
- Mobile Cardiac Telemetry, Wearable Cardiac Monitor
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Minnesota
Cardiotoxicity, Lung Cancer Stage III
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer.
- Conditions
- Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
- Trial name
- CLARITY (NCT04305613)
- Testing
- Chemoradiation
- Where
- 8 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, HER2-positive Breast Cancer
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I
- Trial name
- NCT05036252
- Testing
- Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia, Atrial Fibrillation
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms.
- Conditions
- Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
- Trial name
- SENTINEL (NCT06211413)
- Testing
- no intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Coronary Microvascular Dysfunction, Cardiotoxicity
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy.
- Conditions
- Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- NCT06332131
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiotoxicity, Heart Failure
Novel On-body Evaluation of Cardiac Health for Oncology
The goal of this study is to develop a wearable sensor system that can estimate left ventricular ejection fraction (LVEF), which is a measurement of the heart's function.
- Trial name
- NOECHO (NCT07158450)
- Where
- 11 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Skribe Medical
Cancer
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%).
- Trial name
- CardioTox (NCT04939883)
- Testing
- Carvedilol
- Where
- Brazil
- Volunteers
- 1,018 people
- Sponsor
- Hospital Sirio-Libanes
Cardiotoxicity, DPP3
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year.
- Conditions
- Cardiotoxicity, DPP3, HSCT, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- ALLOCARDIOTOX (NCT07157670)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma Cancer, Breast Cancer
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or…
- Conditions
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma
- Trial name
- NCT07838649
- Testing
- 68Ga-Galmydar, PET/MRI, 18F-FDG
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health.
- Conditions
- Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
- Trial name
- NCT07426913
- Testing
- Cardiovascular Health Education and Gaming through Virtual Reality
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER
Non Small Cell Lung Cancer, Cardiotoxicity
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Trial name
- NCT07761910
- Testing
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Neoplasm Malignant Primary
TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer…
- Trial name
- TRUST-ACE (NCT06310330)
- Testing
- Comprehensive echocardiographic follow-up, Simplified echocardiographic follow-up
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- Norwegian University of Science and Technology